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Abstract
Background: Patients face increasing insurance restrictions on prescription drugs, including generic-only
coverage. There are no generic inhaled corticosteroids (ICS), which are a mainstay of asthma therapy, and
patients pay the full price for these drugs under generic-only policies. We examined changes in ICS use
following the introduction of generic-only coverage in a Medicare Advantage population from 2003–2004.
Methods: Subjects were age 65+, with asthma, prior ICS use, and no chronic obstructive pulmonary
disorder (n = 1,802). In 2004, 74.0% switched from having a $30 brand-copayment plan to a generic-only
coverage plan (restricted coverage); 26% had $15–25 brand copayments in 2003–2004 (unrestricted
coverage). Using linear difference-in-difference models, we examined annual changes in ICS use (measured
by days-of-supply dispensed). There was a lower-cost ICS available within the study setting and we also
examined changes in drug choice (higher- vs. lower-cost ICS). In multivariable models we adjusted for
socio-demographic, clinical, and asthma characteristics.
Results: In 2003 subjects had an average of 188 days of ICS supply. Restricted compared with unrestricted
coverage was associated with reductions in ICS use from 2003–2004 (-15.5 days-of-supply, 95% confidence
interval (CI): -25.0 to -6.0). Among patients using higher-cost ICS drugs in 2003 (n = 662), more restricted
versus unrestricted coverage subjects switched to the lower-cost ICS in 2004 (39.8% vs. 10.3%).
Restricted coverage was not associated with decreased ICS use (2003–2004) among patients who
switched to the lower-cost ICS (18.7 days-of-supply, CI: -27.5 to 65.0), but was among patients who did
not switch (-38.6 days-of-supply, CI: -57.0 to -20.3). In addition, restricted coverage was associated with
decreases in ICS use among patients with both higher- and lower-risk asthma (-15.0 days-of-supply, CI: -
41.4 to 11.44; and -15.6 days-of-supply, CI: -25.8 to -5.3, respectively).
Conclusion: In this elderly population, patients reduced their already low ICS use in response to losing
drug coverage. Switching to the lower-cost ICS mitigated reductions in use among patients who previously
used higher-cost drugs. Additional work is needed to assess barriers to switching ICS drugs and the clinical
effects of these drug use changes.
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Background
As prescription drug costs continue to rise, public and pri-
vate payers are increasing insurance restrictions and
patient cost-sharing for prescription drugs. Cost-sharing
aims to promote cost-effective drug consumption, such as
greater use of generic drugs or reduced use of clinically
unnecessary drugs, by exposing patients to a greater share
of the costs of treatment. For example, in the United
States, Medicare Part D drug benefits, which were offered
starting in 2006 through a number of private plans,
include high levels of cost-sharing. In 2007, about 70% of
Part D drug plans included a coverage gap (often referred
to as a "doughnut hole") wherein patients lose coverage
for all drugs after their total drug spending exceeds $2,400
and until their out-of-pocket costs reach $3,850. About
27% of plans supplement this coverage gap with generic-
only coverage, under which patients have coverage for
generic drugs, but no coverage for brand-name drugs [1].
Under Medicare Part D cost-sharing arrangements, many
beneficiaries may be at risk for losing drug coverage for
inhaled corticosteroids (ICS) during the coverage gap,
even if they have generic-only coverage supplements,
because no generic ICS formulations are available in the
U.S. Inhaled corticosteroids are the mainstay of treatment
for all forms of asthma, except mild-intermittent [2] and
asthma affects approximately seven percent of Americans
age 65 years and older [3]. Other medications used simi-
larly to control asthma symptoms, such as bronchodila-
tors and theophyllines, have inferior efficacy and/or safety
profiles compared with inhaled corticosteroids [2,4,5].
ICS use is associated with lower rates of emergency depart-
ment (ED) visits, asthma-related hospitalizations, and
mortality [4,6,7].
To gain insight about the impact of brand name drug cov-
erage loss, we examined changes in ICS use among Medi-
care Advantage (MA) beneficiaries whose plans switched
from generic and brand coverage with an annual cap in
2003 to generic-only coverage (i.e., no ICS coverage) in
2004. We compared them with MA enrollees with brand-
name coverage in both 2003 and 2004.
Methods
Setting
We used automated data from Kaiser Permanente-North-
ern California (KPNC), an integrated delivery system that
provides comprehensive medical care to over three mil-
lion members, which included about 280,000 MA benefi-
ciaries. Members could join the KPNC MA plan either by
purchasing individual insurance or through plans supple-
mented by their current or former employers. There was
only one MA plan (i.e., single cost-sharing structure) for
individual subscribers, while employers determined
KPNC cost-sharing levels for patients with employer-sup-
plemented plans.
In 2003 individual MA beneficiaries had $10 generic and
$30 brand copayments, and a $1,000 benefit cap (mean-
ing they paid full member price for drugs after their total
drug expenditures exceeded $1,000 during the year). In
2004, the cap was replaced with generic-only coverage –
i.e., patients paid full member price for brand drugs, and
$10 copayments for generics throughout the year
("restricted coverage"). By contrast, employer-supple-
mented MA beneficiaries paid $10 generic and $15–25
brand copayments 2003–2004, with no other limits
("unrestricted coverage"). Patients' coverage type was
determined by their employment history and enrollees
could not switch between the coverage types (please see
Table 1).
The full member price includes the drug acquisition and
dispensing costs and reflects discounts obtained by the
health system; it is generally lower than local retail prices.
During the study period, KPNC offered one ICS brand,
beclomethasone dipropionate (Qvar), at a significantly
lower member price compared with other inhaled corti-
costeroids. Beclomethasone dipropionate was the most
frequently prescribed ICS within the health system, com-
prising 75% of all ICS prescriptions in our study, and was
followed by fluticasone propionate (Flovent), which com-
prised 23% of ICS prescriptions (i.e., 92% of non-beclom-
ethasone dipropionate prescriptions). The average cost
increase due to loss of coverage for a canister of beclom-
ethasone dipropionate was about $15, compared with
$65 or $110 for fluticasone propionate 110 mcg or 220
Table 1: Summary of drug benefits 2003–2004: unrestricted and restricted coverage groups
Coverage group 2003 2004
Unrestricted Coverage $10 generic copayment $10 generic copayment
$15–25 brand copayment $15–25 brand copayment
Restricted Coverage $10 generic copayment $10 generic copayment
$30 brand copayment No brand coverage (i.e., full-price for brands)
$1,000 annual drug benefit cap No annual drug benefit capBMC Health Services Research 2008, 8:151 http://www.biomedcentral.com/1472-6963/8/151
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mcg, respectively. The KPNC Institutional Review Board
approved the study.
Study population
All subjects included in this study (N = 1,802) were con-
tinuous MA enrollees (January 1, 2003-December 31,
2004), 65+ years old, who met at least one of the follow-
ing criteria as of January 1, 2003: (1) ≥ 1 inpatient admis-
sions with a primary asthma diagnosis in the previous
three years; (2) ≥ 1 ED visits with an asthma diagnosis in
the previous two years; or (3) ≥ 2 outpatient visits with an
asthma diagnosis in the previous two years. Further, all
subjects were dispensed ≥ 30 days-of-supply of an ICS in
both 2002 and 2003. We excluded patients with inpatient
or outpatient chronic obstructive pulmonary disorder
(COPD) diagnoses: ICD-9-CM codes 491 (chronic bron-
chitis), 492 (emphysema), 493.20 (asthma with COPD),
or 496 (COPD) in 2003–2004. We also excluded patients
who were dispensed ipratropium bromide (Atrovent), the
primary pharmacologic therapy for COPD within KPNC
in 2003 or 2004, and patients with Medicaid because they
had substantially lower cost-sharing.
Levels and type of ICS use
We measured ICS use based on days-of-supply dispensed.
Days-of-supply were calculated for each prescription by
multiplying the number of actuations per canister by the
number of canisters dispensed and dividing by the pre-
scribed dose (actuations) and frequency of administra-
tion. We carried over remaining supply from month-to-
month and calculated patients' ICS supply in each month
(standardized to a 30-day month) and year. We consid-
ered beclomethasone dipropionate as "lower-cost", and
all other ICS brands as "higher-cost". We calculated
monthly and annual days-of-supply for lower- and
higher-cost ICS drugs separately. We also classified
patients as either lower- or higher-cost ICS users in each
year by the type with the greater days-of-supply.
Covariates
Comparisons between the restricted and unrestricted cov-
erage groups were adjusted for a number of potential con-
founders including age, gender, and race/ethnicity. Race/
ethnicity was determined based on routine member sur-
veys and inpatient records (we included an unknown cat-
egory with 7.5% of subjects). We constructed a
neighborhood socioeconomic status (SES) indicator
using patients' residential addresses and information
from the 2000 US Census. Neighborhoods were consid-
ered low SES if ≥ 20 percent of residents had average
household incomes below the federal poverty level, or ≥
25 percent of residents ≥ 25 years old had less than a high
school education [8,9]. We adjusted for comorbidity
based on the prospective diagnostic cost group (DxCG)
score, which is similar to the risk-adjustment method
used by the Centers for Medicare and Medicaid Services
[10], and included indicators for coronary artery disease,
diabetes, heart failure, and hypertension based on mem-
bership in the health system's chronic disease registries.
To adjust for asthma severity, we used a number of medi-
cation- and diagnosis-related variables in 2002: number
of rescue medication canisters dispensed, having a high-
dose ICS, any oral steroid dispensed, a high-risk asthma
registry flag (see Table 2 footnote for criteria), and any
asthma-related ED visits or hospitalizations. We also
adjusted for ICS days-of-supply in 2003. We determined
the high-dose thresholds based on the Global Initiative
for Asthma treatment guidelines [2].
Analyses
To adjust for potential confounders, we represented the
covariates via a propensity score [11]. For each subject we
calculated their probability of having generic-only cover-
age in 2004 with a logistic model that included all of the
covariates described above. Based on these predicted
probabilities, we classified patients into propensity score
quintiles [12]. We confirmed that covariate distributions
were comparable across coverage groups within each
quintile and found no statistically significant differences
using Pearson chi-square tests for categorical variables and
t-tests for continuous variables. As a sensitivity test, we
compared propensity score with traditional covariate
adjustment; point estimates and standard errors were sim-
ilar across the methods.
To examine monthly ICS use we used a linear model and
estimated coefficients using a generalized estimating
equation (GEE) approach. The models included indica-
tors for propensity score quintile (2–5), month (2–24),
restricted coverage, and interactions between restricted
coverage and month. The coefficients of the interactions
test the hypothesis that coverage type was associated with
different patterns of ICS use over months.
To examine changes in annual ICS use associated with
restricted coverage we calculated the change in days-of-
supply (2004 minus 2003) for each subject and used this
difference as the outcome in linear models, adjusted for
propensity score quintile. We examined annual changes
among all subjects, among users of higher- and lower-cost
ICSs in 2003, separately, and by type of ICS use in 2004,
separately. We also examined changes in ICS use among
patients identified as having high-risk asthma in the
health system's disease registry, and those with lower-risk
asthma (i.e., no high-risk flag).
Lastly, we examined the patient characteristics associated
with having no ICS use in 2004 using multivariable logis-BMC Health Services Research 2008, 8:151 http://www.biomedcentral.com/1472-6963/8/151
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tic regression, and included the covariates described
above.
Results
Patient characteristics
Table 2 displays the characteristics of the 1,802 study sub-
jects: 1,334 subjects (74%) had restricted, and 468
(26.0%) had unrestricted coverage. As shown in Table 3,
higher-cost ICS users in 2003 were more likely to have
high-risk asthma, prior oral steroid use, and a high ICS
dose level, compared with lower-cost ICS users. In 2003,
the average ICS days-of-supply dispensed was 187.5 (sup-
ply for 51.4% of days). In 2004, use decreased for all
groups; overall, patients had an average of 161.3 days-of-
supply (supply for 44.2% of days).
Monthly ICS use
Figure 1 presents monthly ICS use separately for lower-
and higher-cost ICS users with restricted and unrestricted
coverage. Among lower-cost ICS users in 2003, there was
little difference in ICS use between the coverage groups
throughout the study period. Among higher-cost ICS users
in 2003, restricted coverage patients decreased their ICS
use relative to unrestricted coverage patients toward the
end of 2003, as an increasing number of restricted cover-
age subjects exceeded the $1,000 benefit cap (Table 2),
and these differences remained in 2004 after the loss of
brand-name coverage.
Changes in ICS type
Figure 2 displays the distribution of the type of ICS use in
2004 (lower-cost versus higher-cost), by patients' type of
ICS use in 2003 and coverage group. Overall, 13.9% of
subjects had no ICS use in 2004. Among higher-cost ICS
users in 2003, 16.2% of restricted and 9.7% of unre-
stricted coverage patients had no ICS use in 2004 (p =
0.036). In addition, 39.8% of restricted versus 10.3% of
unrestricted coverage patients switched to the lower-cost
ICS in 2004 (p < .001). Among lower-cost ICS users in
2003, levels of non-use of ICS drugs in 2004 were similar
for unrestricted and restricted coverage patients; switching
to higher-cost ICS drugs was uncommon in both groups,
but higher in the unrestricted coverage group (4.1% ver-
sus 1.5%, p = 0.010).
Table 2: Study population: patient characteristics
Total Unrestricted Coverage Restricted Coverage
Characteristic Lower-cost ICS User in
2003
Higher-cost ICS User in
2003
Lower-cost ICS User in
2003
Higher-cost ICS User in
2003
No. subjects 1,802 293 175 847 487
Female* 67.7% 63.8% 65.7% 68.8% 68.8%
Age: 65–74 63.5% 60.4% 57.7% 62.6% 69.2%
75–84 31.4% 33.8% 38.9% 31.6% 26.7%
85+ 5.1% 5.8% 3.4% 5.8% 4.1%
Race/ethnicity*: White 68.1% 71.0% 70.3% 67.1% 67.4%
Black 4.4% 7.2% 6.3% 2.8% 4.9%
Hispanic 6.9% 3.1% 2.9% 8.5% 8.0%
Asian 10.8% 10.6% 12.6% 10.5% 10.9%
Other 3.2% 3.8% 3.4% 3.1% 3.1%
Unknown 6.5% 4.4% 4.6% 8.0% 5.8%
Neighborhood SES*: 
Non-low
80.4% 84.0% 83.4% 78.3% 80.9%
Low 17.7% 14.3% 14.9% 19.5% 17.7%
Unknown 1.9% 1.7% 1.7% 2.2% 1.4%
Coronary Artery Disease 10.9% 11.3% 12.6% 10.6% 10.5%
Diabetes 15.5% 14.0% 15.4% 15.9% 15.6%
Heart Failure* 5.7% 8.2% 6.9% 5.4% 4.1%
Hypertension 55.9% 61.8% 55.4% 56.9% 50.7%
Exceeded $1,000 drug 
cap in 2003
-- -- -- 21.3% 44.2%
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Comorbidity (DxCG) 
score*
0.94 (0.57) 1.00 (0.65) 1.02 (0.60) 0.94 (0.57) 0.89 (0.51)
Notes: Lower-cost ICS Users in 2003 defined as patients with greater use of lower-cost than higher-cost ICS drugs in 2003. The 2003 diagnostic 
cost group (DxCG) score was calculated based on prior year diagnoses and procedures [DxCG Inc., Waltham, MA]. The range for the DxCG 
score was 0.24 to 5.48, median = 0.79.
* p < .05 for difference between unrestricted and restricted coverageBMC Health Services Research 2008, 8:151 http://www.biomedcentral.com/1472-6963/8/151
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Annual changes in ICS use
Table 4 presents the associations between coverage type
and changes in ICS use from 2003 to 2004, adjusted for
covariables. Overall, restricted coverage patients reduced
their ICS use by an average of 15.5 days-of-supply (95%
confidence interval (CI): -25.0 to -6.0) more than unre-
stricted coverage patients. Among lower-cost ICS users in
2003, restricted coverage was associated with a reduction
of 12.8 days-of-supply (CI: -24.3 to -1.3); among higher-
cost ICS users in 2003, restricted coverage was associated
with a reduction of 21.8 days-of-supply (CI: -38.5 to -5.1).
For higher-cost ICS users in 2003, the effect of restricted
coverage on ICS use differed by the type of medication
used in 2004. Restricted coverage was not associated with
decreased ICS use (2003–2004) among patients who
switched to the lower-cost ICS in 2004 (18.7 days-of-sup-
ply, CI: -27.5 to 65.0), but was among patients who did
not switch (-38.6 days-of-supply, CI: -57.0 to -20.3).
We also examined changes in ICS use associated with
restricted coverage, stratified by asthma disease severity, as
defined by having a high-risk asthma flag in the disease
registry (Table 5). Table 5 also presents levels of ICS use in
each group in 2003. As expected, baseline ICS use was
greater among higher-risk asthma patients as compared
with lower-risk within each of the coverage groups; how-
ever, differences by severity level were relatively small
among patients with coverage restrictions as compared
with those without restrictions in either year (difference of
11.6 vs. 29.9 days-of-supply). In contrast, restricted cover-
age was associated with similar reductions in ICS use in
the higher-risk (-15.0 days-of-supply, CI: -41.4 to 11.4)
and lower-risk (-15.6 days-of-supply, CI: -25.8 to -5.3)
asthma groups.
Characteristics associated with no ICS use in 2004
In separate analyses (more details available upon
request), among all subjects and among higher-cost ICS
users in 2003, restricted coverage was not significantly
associated with having no ICS use in 2004 (OR = 1.18, CI:
0.83–1.67; and OR = 1.65, CI: 0.89–3.04, respectively).
Among all subjects, having a high-dose ICS in 2002 and
greater ICS use (days-of-supply) in 2003 were associated
with lower odds of no ICS use in 2004 (OR = 0.65, CI:
0.46–0.92; and OR = 0.89, CI: 0.87–0.91, respectively).
Discussion
Inhaled corticosteroids are a critical component of ther-
apy for persistent asthma. In this population of Medicare
beneficiaries with asthma, levels of ICS use were low (as
shown in Table 3): on average, patients had drug supply
for only about half of the year in 2003. Moreover, loss of
Table 3: Study population: asthma characteristics
Unrestricted Coverage Restricted Coverage
Characteristic Total Lower-cost ICS User
in 2003
Higher-cost ICS User
in 2003
Lower-cost ICS User
in 2003
Higher-cost ICS User
in 2003
No. subjects 1,802 293 175 847 487
High-risk asthma flag in 2002* 12.1% 10.9% 17.1% 9.0% 16.4%
ED visit or hospitalization for 
asthma in 2002
6.7% 9.2% 5.1% 5.3% 8.2%
Oral steroid Rx dispensed in 
2002
31.4% 27.7% 32.6% 27.5% 39.8%
Low ICS dose level in 2002 31.4% 55.3% 10.9% 53.5% 14.0%
Medium ICS dose level in 
2002
36.2% 36.5% 37.1% 36.6% 35.1%
High ICS dose level in 2002 24.8% 8.2% 52.0% 9.9% 50.9%
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
No. of rescue medication 
canisters dispensed in 2002
3.73 (4.79) 3.57 (4.80) 4.06 (5.10) 3.44 (4.12) 4.18 (5.64)
ICS Days-of-supply in 2003** 187.5 (103.3) 200.0 (107.2) 204.4 (104.3) 187.8 (102.7) 173.4 (99.9)
ICS Days-of-supply in 2004** 161.3 (120.3) 184.7 (124.7) 184.4 (119.0) 162.0 (120.9) 137.5 (112.8)
Notes: Lower-cost ICS Users in 2003 defined as patients with greater use of lower-cost than higher-cost ICS drugs in 2003. ICS dose level 
categorized based on the first prescription in 2002 and the Global Initiative for Asthma treatment guidelines.
* The registry classified patients as high-risk if they met any of the following criteria: (1) ≥ 1 inpatient admissions with a primary asthma diagnosis in 
the previous 12 months, (2) ≥ 1 inpatient admissions with a secondary asthma diagnosis in the previous 12 months, accompanied by a primary 
asthma-related diagnosis, (3) ≥ 1 ED visits with an asthma diagnosis in the previous six months, (4) ≥ 5 prescriptions for asthma medication in the 
previous six months with ≥ 2 oral steroid prescriptions in the previous 12 months, or (5) ≥ 12 canisters of inhaled beta-agonists in the previous 12 
months.
** p < .05 for difference between unrestricted and restricted coverage groupsBMC Health Services Research 2008, 8:151 http://www.biomedcentral.com/1472-6963/8/151
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coverage for ICS drugs in 2004 was associated with reduc-
tions in ICS use.
Restricted drug coverage was associated with a modest
reduction in ICS use even among patients who faced
smaller increases in out-of-pocket costs because they were
using the lower-cost ICS in 2003 before the loss of brand-
name coverage. Changes in ICS use from 2003 to 2004
were more pronounced among the one-third of patients
who were prescribed higher-cost inhaled corticosteroids
in 2003. As expected, a number of these patients with
restricted coverage switched to the lower-cost drug in
2004 (about 40 percent), and switching appeared to mit-
igate reductions in 2004 ICS use due to loss of drug cover-
age. However, many patients did not switch to the lower-
cost ICS and those with restricted coverage reduced their
ICS use by over one month of supply compared with
patients with unrestricted coverage.
Patients who were taking higher-cost ICS drugs at baseline
exhibited greater asthma severity compared with lower-
cost ICS users, as indicated by several medication and
diagnoses measures shown in Table 3. In addition, in
analyses stratified by asthma severity level (Table 5), loss
of brand-name drug coverage was associated with reduc-
tions in ICS use, even among those with a strong clinical
indication for the drug therapy (i.e., higher-risk asthma
patients). Decreases in ICS use in the high-risk asthma
group may reflect greater increases in drug costs associated
with the loss of coverage, due to higher average daily
doses. Alternatively, the high-risk asthma flag indicates a
prior history of frequent or serious exacerbations, which
may be associated with worse self-management of asthma
symptoms. These findings raise important questions
about potential adverse clinical consequences of reduced
ICS use due to restrictive drug coverage policies, particu-
larly for patients with greater clinical need for ICS therapy.
Studies in non-elderly asthma populations have found
that lower levels of ICS use are associated with greater hos-
Adjusted mean monthly ICS days-of-supply (2003–2004) for lower-cost and higher-cost ICS users in 2003 by coverage group Figure 1
Adjusted mean monthly ICS days-of-supply (2003–2004) for lower-cost and higher-cost ICS users in 2003 by 
coverage group. Note: The graph presents the adjusted mean monthly days-of-supply (standardized to a 30-day month) of all 
inhaled corticosteroids for the Unrestricted and Restricted Coverage groups. Bars represent 95% confidence intervals.
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pitalizations, emergency department visits, and oral ster-
oid use [6,13,14]. In addition, evidence suggests that
increases in drug costs associated with ICS use are off-set
by decreases in other direct medical costs [15-19].
Research is needed to assess clinical outcomes associated
with these drug coverage policies, as well as to determine
the impact on total medical costs.
Encouraging greater substitution of higher-cost with
lower-cost ICS drugs could mitigate potential adverse
effects of restricted drug coverage policies. In this setting,
switching to the lower-cost ICS would not be likely to
result in adverse clinical effects as head-to-head trials have
not produced definitive conclusions on the comparative
efficacy of different inhaled corticosteroids [5]. There is
some evidence that suggests that potency, or the dose nec-
Table 4: Adjusted change in annual ICS days-of-supply for lower and higher-cost ICS users in 2003: restricted vs. unrestricted coverage
Change in ICS Days-of-Supply 
from 2003 to 2004
Change in ICS Days-of-Supply from 2003 to 2004: Restricted 
vs. Unrestricted Coverage (Difference-in-difference)
Restricted 
Coverage
Unrestricted 
Coverage
Restricted vs. 
Unrestricted
(95% CI) p-value
All Subjects 
(n = 1,802)
-30.27 -14.81 -15.47 (-24.98, -5.95) 0.001
Lower-cost ICS Users in 2003 
(n = 1,140)
-26.38 -13.55 -12.84 (-24.34, -1.33) 0.029
Continued using lower-cost ICS in 
2004 (n = 960)
-13.08 0.63 -13.71 (-25.52, -1.90) 0.023
Switched to higher-cost ICS in 
2004 
(n = 25)
-54.24 29.51 -83.75 (-171.58, 4.07) 0.060
Higher-cost ICS Users in 2003 
(n = 662)
-37.40 -15.60 -21.80 (-38.46, -5.13) 0.010
Continued using higher-cost ICS in 
2004 (n = 354)
-39.81 -1.19 -38.62 (-56.96, -20.28) < .001
Switched to lower-cost ICS in 2004 
(n = 212)
0.71 -18.04 18.75 (-27.46, 64.96) 0.425
Notes: Each row represents a separate OLS regression model. Among lower-cost ICS users in 2003, 155 subjects had no ICS drug use in 2004, 
among higher-cost ICS users in 2003, 96 subjects had no ICS drug use in 2004. We calculated mean changes in ICS days-of-supply for each coverage 
group by using the lincom command in Stata 8.2 and the mean levels of the covariables.
Type of ICS use in 2004 by coverage group and type of ICS use in 2003 Figure 2
Type of ICS use in 2004 by coverage group and type of ICS use in 2003. Note: Lower-cost ICS Users in 2003 and 
2004 were defined as patients with greater use of lower-cost than higher-cost ICS drugs in each year, and vice-versa. Patients 
were defined as having No ICS Use in 2004 if their total annual ICS days-of-supply was zero.
82.6% 84.8% 80.0%
43.9%
10.3%
39.8%
13.3% 13.7% 9.7% 16.2%
4.1% 1.5%
0%
20%
40%
60%
80%
100%
Unrestricted
coverage
Restricted
coverage
Unrestricted
coverage
Restricted
coverage
P
e
r
c
e
n
t
 
o
f
 
s
u
b
j
e
c
t
s
No ICS use in 2004
Switched ICS type in
2004
Continued using
same ICS type in
2004
Lower-cost ICS users in 2003 Higher-cost ICS users in 2003BMC Health Services Research 2008, 8:151 http://www.biomedcentral.com/1472-6963/8/151
Page 8 of 10
(page number not for citation purposes)
essary to achieve a specific effect, may differ across differ-
ent ICS types. Notably, fluticasone propionate (the
primary higher-cost ICS in this study) appears to achieve
similar improvements in lung function at half the dose of
beclomethasone dipropionate (the lower-cost ICS)
[20,21]. Thus, the higher-cost ICS drugs may offer simpler
daily dosing regimens, such as requiring fewer administra-
tions per day, compared with the lower-cost ICS, which
might encourage better regimen adherence especially for
patients prescribed a high ICS dose (i.e., patients with a
more frequent dosing schedule) [22]. More work is
needed to explore whether patients were aware of the
availability of a lower-cost ICS and to examine other
potential barriers to switching.
Poor adherence to ICS therapy has been demonstrated in
other studies [4,23-28]. Two Canadian studies found that
increases in drug cost-sharing were associated with
decreases in ICS use in elderly patients and children
[29,30]. To our knowledge, no studies have examined the
impact of drug coverage restrictions on ICS use in Medi-
care populations. Our findings suggest that patients who
lose coverage for their inhaled corticosteroids may reduce
their levels ICS use. Of importance, this health system was
able to provide a lower price on beclomethasone dipropi-
onate, due to negotiated discounts, than is likely to be
available in other settings. Therefore, our findings of
decreases in ICS use due to generic-only coverage in this
setting raise important questions about the potential for
more pronounced effects in other settings where a lower-
cost ICS is not available. This highlights the importance of
providing patients with a low-cost ICS option during
uncovered periods, such as Part D coverage gaps, to
encourage continued adherence to ICS therapy.
Because ours was a non-randomized study it is possible
that differential changes in ICS use between the restricted
and unrestricted groups are due to unmeasured differ-
ences. We were able to adjust for a large a number of
socio-demographic and clinical characteristics, including
a number of asthma severity measures. Identifying
patients with persistent asthma based on administrative
data is challenging; we examined other cohort definitions
of varying restrictiveness (e.g., including patients with a
secondary inpatient diagnosis of asthma) and found sim-
ilar results across these definitions. ICS use was measured
using pharmacy data. These data do not capture whether
patients actually took dispensed medications or took
them correctly; we also did not assess the clinical effects of
changes in ICS use. The pharmacy data do not include
drugs dispensed outside of KPNC; however, patients had
a financial incentive to purchase their medications within
KPNC because of favorable in-system prices throughout
the study period. As a result, in telephone interviews,
members report rarely going outside of the system to
obtain medications or other services [31]. Lastly, this inte-
grated delivery system may have an enhanced ability to
monitor care and control drug costs, which may minimize
potential harms due to increases in cost-sharing.
Conclusion
This study highlights the importance of offering a low-
cost option within the ICS drug class, particularly during
uncovered periods, such as during the Medicare Part D
coverage gap. Insurers may also consider maintaining cov-
erage for ICS drugs during otherwise uncovered periods
for patients with a clinical need for these drugs. Addi-
tional work is needed to understand patient responses to
drug cost-sharing, especially for patients who did not
switch to the lower-cost option yet reduced ICS use, as
well as the clinical effects of restricted drug coverage poli-
cies.
Abbreviations
CI: confidence interval; COPD: chronic obstructive pul-
monary disorder; ED: emergency department; ICS:
inhaled corticosteroids; KPNC: Kaiser Permanente-North-
ern California; MA: Medicare Advantage; OR: odds ratio.
Table 5: Adjusted change in annual ICS days-of-supply for lower and higher-risk asthma patients: restricted vs. unrestricted coverage
Baseline ICS Days-of-
Supply (2003)
Change in ICS Days-of-Supply 
from 2003 to 2004
Change in ICS Days-of-Supply from 2003 to 
2004: Restricted vs. Unrestricted Coverage 
(Difference-in-difference)
Restricted 
Coverage
Unrestricted 
Coverage
Restricted 
Coverage
Unrestricted 
Coverage
Restricted vs. 
Unrestricted
(95% CI) p-value
Lower-risk asthma 
patients (n = 1,584)
181.20 197.70 -30.46 -14.90 -15.56 (-25.77, -5.34) 0.003
Higher-risk asthma 
patients (n = 218)
192.79 227.58 -28.97 -14.00 -14.97 (-41.38, 11.44) 0.265
Notes: Each row represents a separate OLS regression model. We classified those with a high-risk asthma flag as higher-risk and those with no high-
risk flag as lower-risk asthma patients (please see Table 3). We calculated mean changes in ICS days-of-supply for each coverage group by using the 
lincom command in Stata 8.2 and the mean levels of the covariables. The baseline ICS days-of-supply presents the unadjusted mean days-of-supply in 
each group in 2003.BMC Health Services Research 2008, 8:151 http://www.biomedcentral.com/1472-6963/8/151
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